1576PEfficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC

ConclusionsThe combination of bemcentinib and pembro was well tolerated and showed promising efficacy in previously treated IO-na ïve NSCLC pts, particularly in those with AXL positive disease, including PD-L1 negative pts. mOS of >  12 mos is favorable compared with historical references in the NSCLC second-line setting.Clinical trial identificationNCT03184571.Legal entity responsible for the studyBerGenBio ASA.FundingBerGenBio ASA.DisclosureJ.M. Trigo Perez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD. E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Blueprint Medicines; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Speaker Bureau / E...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Abstract LESSONS LEARNED: The biweekly GEM plus CBDCA dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.The biweekly GEM plus CBDCA regimen could be considered an alternative to the 3-week regimen in NSCLC. BACKGROUND: The gemcitabine (GEM)-carboplatin (CBDCA) combination is widely used for non-small cell lung cancer (NSCLC) and has some efficacy in elderly patients; however, a high incidence of thrombocytopenia is observed, and the optimal dosage and administration schedules are unknown. This multicenter phase II trial evaluated the efficacy and toler...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Conclusion: Data from our study suggest nivolumab is well-tolerated and effective in Indian patients with recurrent advanced NSCLC after failure of the multiple first lines of platinum-based combination chemotherapy.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractBackgroundThe VNR/Cis chemotherapy doublet has been evaluated in prior positive adjuvant trials in patients with completely resected Ns-NSCLC, whereas no phase III study has so far evaluated PEM/Cis in this population. And there are few data regarding outcomes based on EGFR mutation (EGFRm) status in adjuvant chemotherapies.MethodsPatients with completely resected Ns-NSCLC were randomized in a 1:1 ratio to receive either PEM (500  mg/m2, day 1)/Cis (75  mg/m2, day 1) or VNR (25  mg/m2, days 1 and 8)/Cis (80  mg/m2, day 1), and stratified according to sex, age, pathologic stage, EGFRm sta...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile. The antitumor activity of the ibrutinib-durvalumab combination was limited in our study population.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile. The antitumor activity of the ibrutinib-durvalumab combination was limited in our study population. PMID: 31230047 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This article presented a case of a human leukocyte antigen (HLA)-A2-positive patient with advanced cancer/testis antigen New York esophageal squamous cell carcinoma-1 (NY-ESO-1) expressing lung adenocarcinoma (LADC) who received adoptive cell therapy of T cell receptor engineered-T cells (TCR-T cells) targeting the cancer-testis antigen NY-ESO-1. The appropriate clinical and laboratory assessments were conducted to investigate the safety and efficacy of this therapy for this lung cancer patient. The patient had a clinical response to and was well-tolerated with this therapy in the clinical trial. In addition, a preliminary...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
CONCLUSIONS: Dabrafenib + trametinib was well tolerated and demonstrated a high rate of durable responses in patients with heavily pretreated recurrent/refractory BRAF V600E-mutated HCL.DisclosuresKreitman: NIH: Patents &Royalties: Co-inventor on the NIH patent for Moxetumomab Pasudotox. Moreau: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors ...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma Source Type: research
ConclusionThis combined regimen shows efficacy and a manageable safety profile. PFS and OS outcomes are encouraging and warrant further research.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: From our experience, for patients with good PS, diagnosed with advanced lung adenocarcinoma, PCMT shows clinically meaningful survival benefits and important response rates, while maintaining a reasonable safety profile.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
More News: Adenocarcinoma | Anemia | AstraZeneca | Cancer & Oncology | Chemotherapy | Clinical Trials | Employment | Grants | History of Medicine | Legislation | Merck | Non-Small Cell Lung Cancer | PET Scan | Pfizer | Smokers